Neuberger Berman Group
VIRX

Neuberger Berman Group’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Neuberger Berman Group’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-4,016
Closed -$576K – 1664
2017
Q1 		$576K Buy
4,016
+572
+17% +$81.8K ﹤0.01% 1275
2016
Q4 		$436K Buy
+3,444
New +$479K ﹤0.01% 1318

Other funds holding VIRX

Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Neuberger Berman Group's VIRX Position: Q2 2017 in Review

Neuberger Berman Group sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q2 2017, closing a stake of 4,016 shares — an estimated $576K sold.

Neuberger Berman Group first reported a position in VIRX in Q4 2016 and held it in 2 quarters. The position peaked at $576K in Q1 2017. 37 funds tracked by Wall St. Rank hold VIRX as of Q2 2017.

  • Neuberger Berman Group reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q2 2017 after selling out during the quarter.
  • Neuberger Berman Group sold 4,016 Viracta Therapeutics, Inc. Common Stock shares in Q2 2017, an estimated $576K.
  • Neuberger Berman Group first reported a position in Viracta Therapeutics, Inc. Common Stock in Q4 2016 and held it in 2 quarters.
  • Neuberger Berman Group's Viracta Therapeutics, Inc. Common Stock position peaked at $576K in Q1 2017.
  • 37 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q2 2017.

Based on Neuberger Berman Group's 13F filing for Q2 2017, filed 8 Aug 2017.